Replies to post #171611 on Biotech Values

[DewDiligence]

GLYC IPO’d Thursday at $8.00 and closed Friday at $9.01:

http://www.glycomimetics.com/2014/01/glycomimetics-announces-pricing-of-initial-public-offering/

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

8.1M shares will be sold at the IPO price assuming the underwriter’s option is exercised.

Does anyone here own or follow this company?